These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 38203521)

  • 1. Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications.
    Weng S; Yang X; Yu N; Wang PC; Xiong S; Ruan H
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial RNA Editing with ADAR for Gene Therapy.
    Bhakta S; Tsukahara T
    Curr Gene Ther; 2020; 20(1):44-54. PubMed ID: 32416688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and implications of ADAR-mediated RNA editing in cancer.
    Wang C; Zou J; Ma X; Wang E; Peng G
    Cancer Lett; 2017 Dec; 411():27-34. PubMed ID: 28974449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity.
    Roth SH; Levanon EY; Eisenberg E
    Nat Methods; 2019 Nov; 16(11):1131-1138. PubMed ID: 31636457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS; Ben-Asher N; Lamm AT
    Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in ADAR RNA editing patterns in CMV and ZIKV congenital infections.
    Wales-McGrath B; Mercer H; Piontkivska H
    BMC Genomics; 2023 Nov; 24(1):685. PubMed ID: 37968596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine-to-Inosine RNA Editing in Health and Disease.
    Gatsiou A; Vlachogiannis N; Lunella FF; Sachse M; Stellos K
    Antioxid Redox Signal; 2018 Sep; 29(9):846-863. PubMed ID: 28762759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmable RNA editing with endogenous ADAR enzymes - a feasible option for the treatment of inherited retinal disease?
    Bellingrath JS; McClements ME; Fischer MD; MacLaren RE
    Front Mol Neurosci; 2023; 16():1092913. PubMed ID: 37293541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. irCLASH reveals RNA substrates recognized by human ADARs.
    Song Y; Yang W; Fu Q; Wu L; Zhao X; Zhang Y; Zhang R
    Nat Struct Mol Biol; 2020 Apr; 27(4):351-362. PubMed ID: 32203492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A-to-I RNA editing - thinking beyond the single nucleotide.
    Ganem NS; Lamm AT
    RNA Biol; 2017 Dec; 14(12):1690-1694. PubMed ID: 28820319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models to elucidate the functional roles of adenosine-to-inosine editing.
    Rula EY; Emeson RB
    Methods Enzymol; 2007; 424():333-67. PubMed ID: 17662849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALU A-to-I RNA Editing: Millions of Sites and Many Open Questions.
    Schaffer AA; Levanon EY
    Methods Mol Biol; 2021; 2181():149-162. PubMed ID: 32729079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for recruiting endogenous and exogenous ADAR enzymes for site-specific RNA editing.
    Xiang Y; Katrekar D; Mali P
    Methods; 2022 Sep; 205():158-166. PubMed ID: 35779766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.
    Wang Y; Liang H
    Bioessays; 2018 Feb; 40(2):. PubMed ID: 29280160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies for Site-Directed RNA Editing using ADARs.
    Montiel-Gonzalez MF; Diaz Quiroz JF; Rosenthal JJC
    Methods; 2019 Mar; 156():16-24. PubMed ID: 30502398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine-to-inosine RNA editing: perspectives and predictions.
    Hoopengardner B
    Mini Rev Med Chem; 2006 Nov; 6(11):1213-6. PubMed ID: 17100632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic identification of abundant A-to-I editing sites in the human transcriptome.
    Levanon EY; Eisenberg E; Yelin R; Nemzer S; Hallegger M; Shemesh R; Fligelman ZY; Shoshan A; Pollock SR; Sztybel D; Olshansky M; Rechavi G; Jantsch MF
    Nat Biotechnol; 2004 Aug; 22(8):1001-5. PubMed ID: 15258596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A-to-I RNA editing and cancer: from pathology to basic science.
    Gallo A; Galardi S
    RNA Biol; 2008; 5(3):135-9. PubMed ID: 18758244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADARs, RNA editing and more in hematological malignancies.
    Teoh PJ; Koh MY; Chng WJ
    Leukemia; 2021 Feb; 35(2):346-359. PubMed ID: 33139858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine-to-inosine RNA editing and human disease.
    Slotkin W; Nishikura K
    Genome Med; 2013; 5(11):105. PubMed ID: 24289319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.